5 Reasons Why Pfizer Is a Better Stock to Buy Right Now Than Moderna

10:52am, Thursday, 13'th Jan 2022 The Motley Fool
It's not even close.
These businesses are in great positions to raise their dividends, buy back shares, or grow their operations.
Arena Pharmaceuticals Inc (ARNA) shares closed today at 1.0% below its 52 week high of $94.08, giving the company a market cap of $5B. The stock is currently up 0.3% year-to-date, up 20.8% over the past 12 months, and up 517.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 32.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -105.6% The company's stock price performance over the past 12 months beats the peer average by -158.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

3 No-Brainer Big Pharma Stocks to Buy in 2022

02:27pm, Sunday, 09'th Jan 2022 The Motley Fool
There's a lot to like about each of these companies.
Arena Pharmaceuticals Inc (ARNA) shares closed today at 1.0% below its 52 week high of $94.08, giving the company a market cap of $5B. The stock is currently up 0.3% year-to-date, up 20.1% over the past 12 months, and up 517.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 32.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 0.1% higher than its 5-day moving average, 3.4% higher than its 20-day moving average, and 41.3% higher than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -105.6% The company's stock price performance over the past 12 months beats the peer average by -157.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

1 Big Question Facing Moderna in 2022

03:30pm, Saturday, 08'th Jan 2022 The Motley Fool
This question could make or break the stock in the years ahead.

3 Stocks to Buy for 2022 That Are Practically Money Machines

10:52am, Tuesday, 04'th Jan 2022 The Motley Fool
All of them should generate even greater cash flow in the new year than they did in 2021.
Arena Pharmaceuticals Inc (ARNA) shares closed today at 0.9% below its 52 week high of $94.08, giving the company a market cap of $5B. The stock is currently flat year-to-date, up 21.0% over the past 12 months, and up 554.5% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.9%. Trading Activity Trading volume this week was 54.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date is the same as the peer average. The company's stock price performance over the past 12 months beats the peer average by -173.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Here's Why Pfizer (PFE) Appears Strongly Placed for 2022

02:23pm, Monday, 03'rd Jan 2022 Zacks Investment Research
While the COVID vaccine should continue to boost Pfizer (PFE) revenues in 2022, Paxlovid is also likely to become an important top-line driver

Are Options Traders Betting on a Big Move in Arena (ARNA) Stock?

01:34pm, Monday, 03'rd Jan 2022 Zacks Investment Research
Investors need to pay close attention to Arena (ARNA) stock based on the movements in the options market lately.
Arena Pharmaceuticals Inc (ARNA) shares closed today at 1.2% below its 52 week high of $94.08, giving the company a market cap of $5B. The stock is currently up 20.6% year-to-date, up 18.1% over the past 12 months, and up 517.8% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 42.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -173.7% The company's stock price performance over the past 12 months beats the peer average by -166.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.
Pfizer's pending acquisition of Arena Pharma includes Olorinab, a candidate that acts with the cannabinoid type 2 receptor to treat gastrointestinal disorders.

MarkIt to Market® - December 2021

03:54pm, Thursday, 23'rd Dec 2021 JD Supra
The December 2021 issue of Sterne Kessler''s MarkIt to Market® newsletter discusses new enforcement tools courtesy of the Trademark Modernization Act; Pfizer''s acquisition of Arena Pharmaceuticals; the latest developments in Canopy Growth''s patent infringement suit against GW Pharmaceuticals; and the open gTLD Sunrise period. This year, Sterne Kessler''s Trademark & Brand Protection team continued its support of Stockings from Karen, an organization that provides toiletries and gifts for teenage By: Sterne, Kessler, Goldstein & Fox P.L.L.C.
Volatility is falling and market breadth is improving, suggesting investors may soon step in and buy stocks.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE